Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Cytochrome P450 3A4 (CYP3A4) is the most abundant drug-metabolizing enzyme in the human liver, responsible for processing approximately 50% of all pharmaceuticals and many endogenous compounds. This heme-containing enzyme facilitates phase I metabolism through hydroxylation, dealkylation, and oxidation reactions, playing a crucial role in drug clearance and toxin elimination.
Reported Benefits (Provisional)
Origin & History
CYP3A4 is a member of the cytochrome P450 superfamily of enzymes, primarily found in the liver and intestines. It is involved in the metabolism of many drugs and toxins. It is produced by the body and plays a critical role in drug metabolism and synthesis of cholesterol, steroids, and other lipids.
Research Narrative (Provisional)
CYP3A4 has been extensively studied in pharmacokinetics and drug interaction research. Numerous studies, including randomized controlled trials and meta-analyses, have explored its role in drug metabolism. In vitro studies have provided insights into its enzymatic activity and substrate specificity.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
- Not applicable as CYP3A4 is an endogenous enzyme. - Primarily located in the liver and intestines. - Involved in oxidative metabolism of a wide range of substrates.
Reported Mechanism (Provisional)
CYP3A4 operates through heme-mediated oxidation reactions, utilizing NADPH-cytochrome P450 reductase as an electron donor to activate molecular oxygen. The enzyme catalyzes hydroxylation, N-dealkylation, and epoxidation of substrates including steroids, fatty acids, and xenobiotics. CYP3A4 expression is regulated by nuclear receptors PXR and CAR, which respond to substrate exposure by increasing enzyme transcription.
Clinical Narrative (Provisional)
Clinical studies demonstrate significant inter-individual variability in CYP3A4 activity, ranging from 10-40 fold differences between individuals due to genetic polymorphisms and environmental factors. Pharmacokinetic studies show that CYP3A4 inhibitors like ketoconazole can increase substrate drug concentrations by 300-2000%, while inducers like rifampin reduce concentrations by 70-90%. Population studies indicate that CYP3A4 activity declines with age and differs between ethnicities, with important implications for drug dosing strategies.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.